E-DRUG: COX-2 in New England Journal of Medicine
Dear colleagues,
Early release from the New England Journal of Medicine
(posted February 15, 2005)
Original Articles
-------------------------
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention <http://content.nejm.org/cgi/reprint/NEJMoa050405v1.pdf>http://content.nejm.org/cgi/reprint/NEJMoa050405v1.pdf
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
http://content.nejm.org/cgi/reprint/NEJMoa050330v1.pdf
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
http://content.nejm.org/cgi/reprint/NEJMoa050493v1.pdf
Editorials
--------------
COX-2 Inhibitors -- A Lesson in Unexpected Problems
http://content.nejm.org/cgi/reprint/NEJMe058038v1.pdf
COX-2 Inhibitors -- Lessons in Drug Safety
http://content.nejm.org/cgi/reprint/NEJMe058042v1.pdf
Kind regards,
Leela McCullough, Ed.D.
Director of Information Services
SATELLIFE
30 California Street, Watertown, MA 02472, USA
Tel: +617-926-9400 Fax: +617-926-1212
Email: leela@healthnet.org
Web: http://www.healthnet.org